Vivienne I. Rebel, M.D., Ph.D., Executive Vice President of Research and Development, Chief Medical and Science Officer is a cancer (stem) cell biologist, with more than 20 years of experience in scientific research, focused on understanding the molecular events that lead to cancer development.  She joined bioAffinity Technologies after leaving her position as a National Institutes of Health (NIH)-funded Associate Professor in the Department of Cellular and Structural Biology and Scientific Advisor to the Flow Cytometry Core Facility at the University of Texas Health Science Center, San Antonio, Texas.  Dr. Rebel was awarded The UT Health Science Center 2012 Cancer Therapy and Research Center’s “Discovery of the Year” Award for her work on the bone marrow microenvironment leading to loss of stem cells and excessive myelopoiesis in a hematopoietic malignancy syndrome, called Myelodysplastic Syndrome.  Dr. Rebel performed her doctoral work at the Terry Fox Laboratory for Hematology/Oncology in Vancouver, B.C., Canada, world-renowned for its work in experimental stem cell biology.  She completed her post-doctoral training at the Dana-Farber Cancer Institute, Harvard Medical School in cancer biology and gene therapy. Click here for a listing of Dr. Rebel’s publications.

William Bauta, Ph.D., Senior Vice President of Research and Development, Therapeutics: Dr. Bauta is a medicinal chemist with more than 25 years of experience in discovery, development and commercialization of pharmaceuticals to treat oncology, virology, neuroscience, immunology and metabolic diseases. He joins bioAffinity Technologies from Southwest Research Institute where he helped develop the Institute’s pharmaceuticals services and bioengineering business. Dr. Bauta was Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of multiple therapeutics. He holds several patents and has published in the journal Science and more than a dozen other scientific journals and conference proceedings. Dr. Bauta received his Ph.D. from the University of Chicago. Click here for a listing of Dr. Bauta’s publications.

David Elzi, Ph.D., Director of Basic and Applied Research, brings 20 years of research experience to bioAffinity where he will continue to work on the mechanism of porphyrin uptake in cancer cells and expand CyPath®’s use with other cancers. Dr. Elzi earned his Ph.D. in Molecular and Cellular Biology from the University of Washington, in conjunction with the Fred Hutchinson Cancer Research Center.  He subsequently performed post-doctoral research at the Bonfils Blood Center and University of Colorado Department of Surgery, where he studied the molecular mechanisms of transfusion-related lung injury.  Dr. Elzi comes to bioAffinity from The UT Health Science Center where his research included applying proteomic techniques to study cellular senescence in primary and cancer cells.  He has published more than 20 peer-reviewed articles. Click here for a listing of Dr. Elzi’s publications.

Jamila Rose Sanchez, Ph.D., Senior Manager, Research & Development of Lung Diagnostic is managing optimization and commercialization efforts for bioAffinity Technologies’ CyPath® diagnostic assay for early-stage lung cancer.  She earned her Ph.D. in Cellular and Structural Biology at The University of Texas Health Science Center at San Antonio, where she gained extensive experience with fluorescent microscopy.  Dr. Sanchez’s postdoctoral work included research at the Barshop Institute for Aging and Longevity Studies in San Antonio, Texas, where her work focused primarily on the association between aging and cancer development.  Dr. Sanchez continued her work in cancer research as a postdoctoral associate at the Greehey Children’s Cancer Research Institute under Dr. Vivienne I. Rebel.  She has published five peer-reviewed papers and has four additional manuscripts in preparation for publication. Click here for a listing of Dr. Sanchez’s publications.

Patricia Araujo, PhD, Staff Scientist, is working in the commercialization of CyPath® Lung. A molecular biologist, she has particular experience with proteins and RNAs. Prior to joining bioAffinity Technologies from the UT Health Science Center in San Antonio, Dr. Araujo investigated the networks formed by RNA binding proteins and miRNAs and their connection to biological processes and cancer. She was a Member of the Diversity Committee of the Committee of Cellular and Structural Biology, and has been author or co-author of 17 publications. She earned her PhD in Molecular Biology at the Federal University of Minas Gerais, Belo Horizonte, Brazil. Click here for a listing of Dr. Araujo’s publications.